WO2000053637A1 - INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH η-CYCLODEXTRIN - Google Patents
INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH η-CYCLODEXTRIN Download PDFInfo
- Publication number
- WO2000053637A1 WO2000053637A1 PCT/FR2000/000560 FR0000560W WO0053637A1 WO 2000053637 A1 WO2000053637 A1 WO 2000053637A1 FR 0000560 W FR0000560 W FR 0000560W WO 0053637 A1 WO0053637 A1 WO 0053637A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- fatty acids
- aqueous solution
- complex
- polyunsaturated fatty
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- the invention relates to solubilization
- Polyunsaturated fatty acids such as arachidonic or eicosatetraenoic (AA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids are long chain polyunsaturated fatty acids
- DHA Docosahexaenoic acid
- Triglycerides RR 2 , R 3 represent the fatty acid hydrocarbon group such as EPA, DHA or the like. These n-3 series polyunsaturated fatty acids (PUFA) have very interesting properties in the prevention of certain inflammatory pathologies (psoriasis, arthritis) and cardiovascular diseases.
- PUFA polyunsaturated fatty acids
- n-3 PUFAs exert their beneficial effect by intervening at two levels:
- the period of perinatal development is special in that it corresponds to the most active phase of incorporation of long chain PUFAs (22: 6 n-3; i.e. 22 carbon atoms, 6 ethylenic unsaturations , the first being on carbon n-3) in the structural lipids of the central nervous system, but also the most sensitive to dietary intake of PUFAs.
- this period of rapid growth extends from the last three months of fetal life until the age of two. During the first year, the newborn's brain will take two grams per day mainly due to the phenomenon of myelinization. This implies that dietary intake of PUFA must be quantitatively and qualitatively correct.
- document FR-A-2 547 829 [1] provides a stable composition containing compounds of unsaturated fatty acids and a stabilizing organic compound corresponding to the formula:
- R 1 and R 2 represent Ls respectively fatty acid residues while R represents H 3 or
- Document EP-A-0 470 452 [3] also describes the production of a product comprising ⁇ -cyclodextrin and an oleaginous substance containing EPA or DHA, by precipitation from a solution.
- the present invention specifically relates to formulations in the form of aqueous solutions containing in solution at least one oleaginous substance belonging to the group of polyunsaturated fatty acids and their derivatives (salts, esters and triglycerides), which are suitable for such incorporation.
- the subject of the invention is an aqueous solution comprising at least one oleaginous substance chosen from polyunsaturated fatty acids and the salts, esters and triglycerides of polyunsaturated fatty acids, in which the said substance (s) are in the form of an inclusion complex in ⁇ -cyclodextrin.
- natural cyclodextrins are cyclic oligosaccharides consisting of D-glucopyranosyl units linked in ⁇ -1,4.
- ⁇ -cyclodextrin which is a natural cyclodextrin, comprises eight D-glycopyranosyl units.
- the oleaginous substances used in the invention can be of different types and from various origins, for example from fish or plants.
- the polyunsaturated fatty acids AA, EPA and DHA mentioned above are used, in particular in the form of triglycerides. It is possible to use a mixture of one or more of these acids with other saturated or unsaturated fatty acids, for example a fish oil.
- the solution comprises several oleaginous substances, these being constituted by a fish oil.
- the fish oil can in particular be a sardine oil or a tuna oil.
- Such an oil comprises unsaturated fatty acids having from 1 to 6 ethylenic unsaturations as well as fatty acids without ethylenic unsaturation.
- the invention also relates to a process for the preparation of an aqueous solution comprising at least one oleaginous substance chosen from polyunsaturated fatty acids and the salts, esters and triglycerides of polyunsaturated fatty acids.
- ⁇ -cyclodextrin is used to dissolve these substances and the process comprises the following steps: a) dissolving ⁇ -cyclodextrin in water, b) adding to the solution obtained in a) oleaginous substance (s) to be dissolved, and c) separating the precipitated complex of ⁇ -cyclodextrin and of oleaginous substance (s)
- the precipitated complex can also be recovered, dried, then put back into an aqueous solution.
- the complex obtained can be recovered and dried in the supernatant and then put back into an aqueous solution.
- the method may further comprise a step of recovering and drying at least one of the complexes obtained in step c) followed by the re-solution in aqueous solution of the dried complex (s). .
- one begins by dissolving the ⁇ -cyclodextrin in water with stirring using an amount of ⁇ -cyclodextrin which can go to the saturation of the. solution, i.e. 230 g / 1.
- step b) which follows, the oleaginous substance (s) are added in an amount such that it corresponds to a slight excess relative to the amount of ⁇ -cyclodextrin necessary to form the equimolar complex. It is also subjected to agitation.
- step c) the supernatant is separated from the precipitate, for example by centrifugation.
- oleaginous substances in ⁇ -cyclodextrin overcomes the following problems: the polymerization of polyunsaturated fatty acids, the migration of cis double bonds in trans, and peroxidation.
- Such aqueous formulations can be used to include these polyunsaturated fatty acids and / or their triglycerides, salts and esters in food compositions and in cosmetic compositions.
- the subject of the invention is also pharmaceutical, food or cosmetic compositions comprising an aqueous solution of at least one oleaginous substance chosen from polyunsaturated fatty acids and the salts, esters and triglycerides of polyunsaturated fatty acids, in which the (said) substance (s) are in the form of an inclusion complex in ⁇ -cyclodextrin.
- FIG. 1 is the spectrum obtained by nuclear magnetic resonance of the proton, in pyridine, of the ⁇ -cyclodextrin-fish oil complex, precipitated in the example given below.
- the following example illustrates the solubilization of fish oil using ⁇ -cyclodextrin.
- 9.9931 g of ⁇ -cyclodextrin and 87 ml of water are introduced into a container to obtain a solution of 114.86 g / 1 of ⁇ -cyclodextrin, which corresponds substantially to half of the maximum solubility (230 g / 1) ⁇ -cyclodextrin.
- the mixture is stirred on a turntable at 300 revolutions / minute until the ⁇ -cyclodextrin is completely dissolved, which is obtained in a few minutes.
- TGL (noted TGL in the figure) which are unambiguously attributed to triglycerides from fish oil.
- the amount of triglycerides included in the supernatant is quite large and the amount included in the precipitate is even greater.
- the solubility of the lyophilized complexes is then examined by re-solution in water. To this end, the quantity of water necessary to obtain the dissolution of 0.0846 g of lyophilized complex is added; this is 47.08 ml and it leads to an opalescent solution, the complex concentration of which is 1.79 g / l.
- the lyophilized complex obtained from the supernatant and the lyophilized complex obtained from the precipitate are dissolved in a minimum volume of dimethylformamide DMF, which denatures the complex by separating the two species which constitute it. Having taken a mass of 1 g of complex, a volume of DMF of 4 ml is necessary to dissolve everything. About 60 ml of ether are added to each sample because the triglycerides are soluble therein but not the cyclodextrin which precipitates instantly.
- the fraction of the triglycerides which have been included in the ⁇ -cyclodextrin is thus recovered.
- the fluid obtained is oily in appearance.
- the mass of triglycerides recovered is 0.1178 g per 1 g of the complex from the supernatant and 0.2164 g for 1 g of the complex from the precipitate.
- the samples are stored under argon to avoid any degradation in air, before their analysis by gas chromatography, which will give their characteristic fatty acid profile.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002366719A CA2366719A1 (en) | 1999-03-09 | 2000-03-07 | Solubilization of polyunsaturated fatty acids and their derivatives by formation of inclusion complexes with y-cyclodextrin and their use in pharmaceutical, cosmetic or food compositions |
EP00909441A EP1165620A1 (en) | 1999-03-09 | 2000-03-07 | INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH $g(g)-CYCLODEXTRIN |
JP2000604072A JP2002539138A (en) | 1999-03-09 | 2000-03-07 | Solubilization of polyunsaturated fatty acids and their derivatives by forming inclusion complexes with gamma-cyclodextrin and use of said complexes in pharmaceutical, cosmetic or food compositions |
NO20014341A NO20014341D0 (en) | 1999-03-09 | 2001-09-06 | Dissolution of polyunsaturated fatty acids and derivatives thereof by formation of <gamma> cyclodextrin inclusion compositions and their use in pharmaceutical, cosmetic or food compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/02881 | 1999-03-09 | ||
FR9902881A FR2790758A1 (en) | 1999-03-09 | 1999-03-09 | SOLUBILIZATION OF POLYUNSATURATED FATTY ACIDS AND DERIVATIVES THEREOF BY FORMATION OF INCLUSION COMPLEXES WITH A CYCLODEXTRIN AND THEIR USE IN PHARMACEUTICAL, COSMETIC OR FOOD COMPOSITIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000053637A1 true WO2000053637A1 (en) | 2000-09-14 |
Family
ID=9542970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/000560 WO2000053637A1 (en) | 1999-03-09 | 2000-03-07 | INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH η-CYCLODEXTRIN |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1165620A1 (en) |
JP (1) | JP2002539138A (en) |
CA (1) | CA2366719A1 (en) |
FR (1) | FR2790758A1 (en) |
NO (1) | NO20014341D0 (en) |
WO (1) | WO2000053637A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2209658A1 (en) * | 2002-12-05 | 2004-06-16 | Proyecto Empresarial Brudy, S.L. | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
WO2004080207A1 (en) * | 2003-03-11 | 2004-09-23 | General Mills, Inc. | Cyclodextrin-containing composition and methods |
US7105195B2 (en) | 2003-07-25 | 2006-09-12 | General Mills, Inc. | Reduced trans fat product |
US7335386B2 (en) | 2003-07-30 | 2008-02-26 | Gerneral Mills, Inc. | Method for preventing acrylamide formation in food products and food intermediates |
WO2009136179A1 (en) * | 2008-05-09 | 2009-11-12 | Omegatri As | Topical compositions |
US7667057B2 (en) | 2002-11-14 | 2010-02-23 | Wacker-Chemie Gmbh | Cosmetic composition comprising a complex of cyclodextrin and vitamin F |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2850040B1 (en) * | 2003-01-20 | 2005-03-11 | Centre Nat Rech Scient | SYSTEMS FOR MICROENCAPSULATION AND THEIR APPLICATIONS |
EP1637134A4 (en) * | 2003-06-20 | 2010-01-27 | Mochida Pharm Co Ltd | Composition for prevention/treatment for varicose veins |
EP2049083A2 (en) * | 2006-12-27 | 2009-04-22 | Cargill, Incorporated | Stabilisation by preparing cyclodextrin inclusion complexes |
FR2915901A1 (en) * | 2007-05-07 | 2008-11-14 | In Cyclo Soc Par Actions Simpl | HOMOGENEOUS AND STABLE COMPOSITION, RICH IN OLEAGINOUS SUBSTANCES BASED ON A MILK PRODUCT, PROCESS FOR PREPARING SAME AND USES THEREOF. |
GB0710439D0 (en) * | 2007-05-31 | 2007-07-11 | Uni I Oslo | Oral dosage form |
FR3048177B1 (en) * | 2016-02-25 | 2020-10-30 | Fabre Pierre Dermo Cosmetique | BIPHASE COSMETIC COMPOSITION AND ITS USE BY TOPICAL APPLICATION |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5813541A (en) * | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | Cyclodextrin clathrate compound of eicosapentaenoic acid or docosahexaenoic acid |
JPS5941395A (en) * | 1982-09-01 | 1984-03-07 | マルハ株式会社 | Stabilization of fish oils |
FR2550445A1 (en) * | 1983-08-08 | 1985-02-15 | Hayashibara Biochem Lab | COMPOUND FOR INCLUSION OF EICOSAPENTAENOIC ACID IN GAMMA-CYCLODEXTRIN, FOOD PRODUCT CONTAINING THIS COMPOUND, AND METHODS FOR THEIR PREPARATION |
EP0470452A2 (en) * | 1990-08-09 | 1992-02-12 | Staroil Limited | A method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes |
JPH0725816A (en) * | 1993-07-08 | 1995-01-27 | Yoshihisa Matsuda | Polyenoic acid clathrate |
-
1999
- 1999-03-09 FR FR9902881A patent/FR2790758A1/en active Pending
-
2000
- 2000-03-07 EP EP00909441A patent/EP1165620A1/en not_active Withdrawn
- 2000-03-07 CA CA002366719A patent/CA2366719A1/en not_active Abandoned
- 2000-03-07 WO PCT/FR2000/000560 patent/WO2000053637A1/en not_active Application Discontinuation
- 2000-03-07 JP JP2000604072A patent/JP2002539138A/en not_active Withdrawn
-
2001
- 2001-09-06 NO NO20014341A patent/NO20014341D0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5813541A (en) * | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | Cyclodextrin clathrate compound of eicosapentaenoic acid or docosahexaenoic acid |
GB2104907A (en) * | 1981-07-16 | 1983-03-16 | Kureha Chemical Ind Co Ltd | Cyclodextrin inclusion compound |
JPS5941395A (en) * | 1982-09-01 | 1984-03-07 | マルハ株式会社 | Stabilization of fish oils |
FR2550445A1 (en) * | 1983-08-08 | 1985-02-15 | Hayashibara Biochem Lab | COMPOUND FOR INCLUSION OF EICOSAPENTAENOIC ACID IN GAMMA-CYCLODEXTRIN, FOOD PRODUCT CONTAINING THIS COMPOUND, AND METHODS FOR THEIR PREPARATION |
EP0470452A2 (en) * | 1990-08-09 | 1992-02-12 | Staroil Limited | A method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes |
JPH0725816A (en) * | 1993-07-08 | 1995-01-27 | Yoshihisa Matsuda | Polyenoic acid clathrate |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 121, no. 3, 18 July 1994, Columbus, Ohio, US; abstract no. 30536, "Water-soluble inclusion complexes of fatty acids or their alkali metal salts with methylated cyclodextrins" XP002122499 * |
CHEMICAL ABSTRACTS, vol. 122, no. 20, 15 May 1995, Columbus, Ohio, US; abstract no. 248302, "Preparation of polyenoic acid inclusion compounds with improved solubility and bioavailability" XP002122498 * |
DATABASE WPI Week 198416, Derwent World Patents Index; AN 1984-097033, XP002122500, "Stabilization of fish oil - by reacting with dextrin or cyclodextrin and encapsulating prod." * |
PATENT ABSTRACTS OF JAPAN vol. 007, no. 083 (C - 160) 6 April 1983 (1983-04-06) * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7667057B2 (en) | 2002-11-14 | 2010-02-23 | Wacker-Chemie Gmbh | Cosmetic composition comprising a complex of cyclodextrin and vitamin F |
ES2209658A1 (en) * | 2002-12-05 | 2004-06-16 | Proyecto Empresarial Brudy, S.L. | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
WO2004080207A1 (en) * | 2003-03-11 | 2004-09-23 | General Mills, Inc. | Cyclodextrin-containing composition and methods |
US7105195B2 (en) | 2003-07-25 | 2006-09-12 | General Mills, Inc. | Reduced trans fat product |
US7547459B2 (en) | 2003-07-25 | 2009-06-16 | General Mills, Inc. | Reduced trans fat product |
AU2004260662B2 (en) * | 2003-07-25 | 2010-07-22 | General Mills, Inc. | Reduced trans fat product |
US7335386B2 (en) | 2003-07-30 | 2008-02-26 | Gerneral Mills, Inc. | Method for preventing acrylamide formation in food products and food intermediates |
WO2009136179A1 (en) * | 2008-05-09 | 2009-11-12 | Omegatri As | Topical compositions |
Also Published As
Publication number | Publication date |
---|---|
CA2366719A1 (en) | 2000-09-14 |
JP2002539138A (en) | 2002-11-19 |
NO20014341L (en) | 2001-09-06 |
EP1165620A1 (en) | 2002-01-02 |
FR2790758A1 (en) | 2000-09-15 |
NO20014341D0 (en) | 2001-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003284633B2 (en) | External composition containing polyunsaturated fatty acid or its salt or ester | |
US5189149A (en) | Method for the production of complexes of long chain polyunsaturated fatty acids and their derivatives, with cyclodextrins, and the resulting complexes | |
EP0178442B1 (en) | Process for the selective enrichment of a delta-6 and delta-9 fatty acids containing mixture with delta-6 polyunsaturated fatty acids, the enriched fractions thus obtained and their use | |
EP0124439B1 (en) | Process for the modification of pectins from sugar beets, products obtained and their use | |
WO2000053637A1 (en) | INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH η-CYCLODEXTRIN | |
FR2553662A1 (en) | COMBINED FATTY ACID COMPOSITION FOR REDUCING THE RATES OF TRIGLYCERIDES AND BLOOD CHOLESTEROL | |
WO1994021764A1 (en) | Unsaponifiable materials of vegetable origin and cosmetic compositions containing same | |
FR2626145A1 (en) | PROCESS FOR REMOVING STEROID COMPOUNDS FROM BIOLOGICAL SUBSTANCE | |
EP0374591B1 (en) | Inhibition of cellular adhesion | |
CA2647089A1 (en) | Association of oleaginous substance with a mixture of at least two cyclodextrins | |
EP0796238B1 (en) | Method of stabilizing polyunsaturated fatty acids and their application in therapy and cosmetics | |
FR2515187A1 (en) | STEROID INCLUSION COMPLEXES WITH G-CYCLODEXTRIN, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
WO1979000588A1 (en) | Polyunsaturated aliphatic esters and their use as flavouring and perfuming ingredients | |
JP2024003139A (en) | Dha-rich polyunsaturated fatty acid compositions | |
FR2679109A1 (en) | New anti-aging nutritional or dietary supplements based on a polyunsaturated fatty acid | |
FR2736827A1 (en) | Oil extracted from plant of genus Calophyllum - is used as cosmetic, esp. as filter against wide UV band | |
FR2741533A1 (en) | New process to stabilise poly-unsaturated fatty acids for cosmetic use | |
CH680448A5 (en) | ||
US20070128292A1 (en) | Novel nutraceutical and pharmaceutical compositions and their uses | |
FR2714066A1 (en) | Use of mono-3,6-anhydrocyclodextrins to solubilize a hydrophobic compound and to control the purity of an enantiomer, and process for preparing these cyclodextrins. | |
EP1023039A2 (en) | Use of alkylmonoglucosides as molecular vectors | |
WO2008152226A2 (en) | Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof | |
WO1994002484A1 (en) | Family of porphin ring substances, method of obtaining them from cyanophyceae, and applications as cosmetics and as therapeutic products | |
WO2010136449A1 (en) | Akg composition and use thereof in the production of a drug | |
EP1685120A1 (en) | Colouring hydrosoluble yellow preparation derived from dihydrochalcones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000909441 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914590 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 604072 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2366719 Country of ref document: CA Ref country code: CA Ref document number: 2366719 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000909441 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000909441 Country of ref document: EP |